Oral Carbapenem Wins FDA Approval for cUTIs - Summary - MDSpire

Oral Carbapenem Wins FDA Approval for cUTIs

Tebipenem pivoxil was noninferior to intravenous imipenem-cilastatin in hospitalized adults.

  • By

  • Kathryn Wighton

  • June 17, 2026

  • 2 min

Share

Objective:

To announce the FDA approval of tebipenem pivoxil for treating complicated urinary tract infections (cUTIs).

Approach:
    Key Findings:
    • Oral tebipenem pivoxil performed similarly to intravenous imipenem-cilastatin.
    • Common adverse reactions included diarrhea, headache, nausea, abdominal pain, increased liver enzymes, and Clostridioides difficile infection.
    Interpretation:

    The FDA has approved tebipenem pivoxil as the first oral carbapenem antibiotic in the US for cUTIs.

    Limitations:
    • Patients with allergies to tebipenem pivoxil or other beta-lactam antibacterials should not take the drug.
    • Not suitable for patients with primary or secondary carnitine deficiency or related metabolic errors.
    Conclusion:

    Tebipenem pivoxil is now available for adults with cUTIs who have limited or no oral treatment options.

    Sources:

Original Source(s)

Oral Carbapenem Wins FDA Approval for cUTIs

  • by Kathryn Wighton

  • June 17, 2026

Related Content

FDA Approves Cefepime-Zidebactam Injection

Phase 3 ENHANCE-1 results showed higher composite clinical cure and microbiologic response rates with cefepime-zidebactam vs meropenem in hospitalized adults with complicated urinary tract infection or acute pyelonephritis.

Medical Oddities: Can a Home Be Preventive Care?

This week’s medical plot twists involved ants, architecture, and auditory hallucinations.

FDA Clears Home Urine Collection Kit for STI Testing

The clearance enables a validated mail-in workflow for self-collected urine specimens processed on Roche cobas systems.